News and media

Newsroom

This is LIDDS newsroom. Here you can find our pressrelease archive, financial calendar archive, events & presentation archive, logos and high res images for press.

press

Press releases

events

Events

presentations

Presentations

analysis

Company Analysis

Stockpicker Company Analysis January 13, 2020 - Link to analysis
Avanza’s analysis December 11 2019 - Link to analysis
Redeye’s Company Analysis December 6, 2019 - Link to analysis
Redeye’s company analysis 23 April 2019 - Link to analysis

Photo Library

NanoZolid logo pack
© LIDDS AB

Lidds logo pack – Dark Cerulean
© LIDDS AB

LIDDS logo pack – White
© LIDDS AB

Lidds logo pack – Black
© LIDDS AB

LIDDS labratory
© LIDDS AB

Product image
© LIDDS AB

Monica Walter – CEO
© LIDDS AB

Monica Walter – CEO
© LIDDS AB

Monica Walter – CEO
© LIDDS AB

Anja Peters Ohlsson
© LIDDS AB

Stefan Grudén
© LIDDS AB

Niklas Axén
© LIDDS AB

Martin Johansson
© LIDDS AB

Charlotta Gauffin
© LIDDS AB

Erwin Brenndörfer
© LIDDS AB

Jan Törnell
© LIDDS AB

Daniel Lifveredson
© LIDDS AB

Monica Walter – CEO
© LIDDS AB

IngaLill Forslund Larsson
© LIDDS AB

Maria Forss
© LIDDS AB

Anders Bjartell
© LIDDS AB

Lidds

LIDDS develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment allowing a controlled, sustained and customized release of medication for up to six months.

Visitingadress: Virdings allé 32b, Uppsala
SE-754 50, Sweden. +46 00 44 55 66 info@liddspharma.com

Financial Calendar

Subscribe for news

Press releases

LIDDS AB (publ) Org No.: 556580-2856, Virdings allé 32B, 754 50 UPPSALA, www.liddspharma.com